The British Veterinary Dermatology Study Group (BVDSG) has marked its 50th anniversary at its autumn congress in Edinburgh, bringing together veterinary dermatology specialists to discuss canine atopic dermatitis, skin-barrier biology, allergology, immunotherapy, behaviour and the cutaneous microbiome.
The British Veterinary Dermatology Study Group has celebrated five decades of veterinary dermatology education and professional collaboration at its 2026 autumn meeting, held from 6 to 8 November at Edinburgh Zoo.
The congress combined a scientific continuing-professional-development programme with networking and discussion among veterinary dermatologists, clinicians and researchers.
The anniversary marks an important milestone for a professional community that has helped advance the clinical understanding and management of skin disease in companion animals. The 2026 meeting placed particular emphasis on allergic skin disease and the biological mechanisms underlying chronic dermatological conditions.
Five decades of veterinary dermatology collaboration
The BVDSG was established to support veterinary dermatology through education, scientific exchange and professional development. Its 50th anniversary provides an opportunity to reflect on the evolution of the discipline.
Veterinary dermatology has changed substantially over the past five decades, moving from largely symptom-oriented management towards a more integrated understanding of immunology, skin-barrier function, microbial ecology and environmental triggers.
Chronic pruritic disease is now recognised as a complex interaction between genetic susceptibility, immune responses, epidermal-barrier dysfunction, environmental exposures and microbial changes.
This broader understanding is influencing the development of diagnostics, therapeutics and long-term management strategies.
Canine atopic dermatitis remains a major clinical focus
Canine atopic dermatitis is a chronic inflammatory and pruritic skin disorder associated with hypersensitivity to environmental allergens. Affected dogs may develop persistent itching, erythema, recurrent otitis externa, licking, chewing and secondary bacterial or yeast infections.
The disease can substantially affect quality of life and often requires long-term management. The congress programme explored advances in allergic skin disease, including the role of skin-barrier science and the immune mechanisms that contribute to chronic inflammation.
A key clinical challenge is that atopic dermatitis is not a single-pathway disease. Individual dogs can differ in their allergen sensitivities, skin-barrier characteristics, microbial communities, clinical presentation and treatment response.
Consequently, successful management frequently requires a combination of approaches rather than reliance on a single intervention.
Skin-barrier science: a central area of research
The epidermal barrier plays a fundamental role in maintaining skin hydration and preventing the entry of irritants, allergens and microorganisms. Disruption of this barrier can increase transepidermal water loss and facilitate exposure of immune cells to environmental substances.
In dogs with atopic dermatitis, abnormalities in epidermal structure and barrier function may contribute to disease susceptibility and persistence. Scientific interest in this area includes:
-
Epidermal lipids and ceramides.
-
Filaggrin and other structural proteins.
-
Transepidermal water loss.
-
Skin hydration.
-
Barrier-repair formulations.
-
Interactions between the epidermis and immune system.
These areas are relevant to the development of topical therapies, emollients, shampoos and other products designed to support skin-barrier function.
The cutaneous microbiome and secondary infections
The skin microbiome is another important component of contemporary veterinary dermatology research. Dogs with atopic dermatitis may experience changes in skin microbial communities, including increased abundance of organisms associated with secondary infection.
Staphylococcus pseudintermedius and Malassezia pachydermatis are particularly relevant in clinical dermatology. The relationship between inflammation, barrier dysfunction and microbial imbalance is complex.
A damaged skin barrier can create conditions favourable to microbial overgrowth, while microbial products may further stimulate inflammation and irritation. This creates a potential cycle of pruritus, scratching, barrier damage and secondary infection. Microbiome research is therefore relevant to both therapeutic development and antimicrobial stewardship.
However, microbiome-modulating products need clinical evidence demonstrating meaningful improvements in disease outcomes.
Allergen-specific immunotherapy and long-term disease control
Allergen-specific immunotherapy remains an important option in the management of selected dogs with atopic dermatitis. The approach involves identifying relevant environmental allergens and developing a tailored immunotherapy formulation intended to modify the immune response over time.
The objective is not simply to suppress itching but to alter allergen-specific immune reactivity. Clinical response can vary, and treatment often requires prolonged administration and monitoring. The congress’s focus on allergology and immunotherapy reflects the continuing importance of identifying disease drivers and developing long-term strategies.
Behaviour and the burden of chronic itch
Chronic pruritus can affect more than the skin. Dogs experiencing persistent itching may develop disturbed sleep, restlessness, irritability and changes in behaviour. Owners also face a considerable management burden, particularly when disease requires frequent treatment, repeated veterinary visits and ongoing control of secondary infections.
This makes quality-of-life assessment an important component of dermatology practice. The congress programme’s inclusion of behaviour alongside immunology and allergology reflects a more holistic approach to chronic skin disease.
A rapidly evolving therapeutic landscape
The veterinary dermatology market has seen the development of several targeted therapies and newer treatment strategies. These include:
-
Monoclonal antibodies targeting IL-31.
-
Janus kinase (JAK) inhibitors.
-
Topical anti-inflammatory treatments.
-
Antimicrobial and antiseptic therapies.
-
Barrier-support formulations.
-
Allergen-specific immunotherapy.
-
Nutritional and microbiome-oriented interventions.
The recent USDA licensure of Zoetis’ Cytopoint Plus, designed to provide 75 days of allergic itch relief in dogs, is one example of the continuing innovation in this market.
The expansion of targeted biologics creates new opportunities, but treatment choice must remain individualised and based on veterinary assessment.
Implications for the animal-health industry
The BVDSG anniversary is relevant to manufacturers and developers across the veterinary dermatology value chain. Potential innovation areas include:
Therapeutics: Targeted biologics, oral anti-pruritic medicines and immunomodulatory approaches.
Topical care: Ceramide-based formulations, barrier-repair products and improved antiseptic treatments.
Diagnostics: Allergen testing, cytology, microbial diagnostics and tools to support differential diagnosis.
Microbiome science: Research into the relationship between skin microbial ecology and inflammatory disease.
Clinical education: Continuing professional development for veterinarians managing chronic dermatological conditions.
Digital tools: Clinical scoring systems and monitoring platforms to track pruritus, lesions and treatment response.
For manufacturers, scientific credibility will increasingly depend on controlled clinical studies, transparent product claims and demonstrable improvements in patient outcomes.
Outlook
The BVDSG’s 50th anniversary highlights the value of sustained scientific collaboration in a specialty where chronic disease, complex immune pathways and individual treatment responses create significant clinical challenges.
The focus on canine atopic dermatitis, skin-barrier biology, allergology and the microbiome reflects the direction in which veterinary dermatology is evolving.
For the animal-health industry, the congress reinforces that the next generation of dermatology products will increasingly depend on a deeper understanding of skin biology, targeted immunology and the interaction between the host, environment and microbiome.
